LU88001A1 - Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires - Google Patents

Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires Download PDF

Info

Publication number
LU88001A1
LU88001A1 LU88001A LU88001A LU88001A1 LU 88001 A1 LU88001 A1 LU 88001A1 LU 88001 A LU88001 A LU 88001A LU 88001 A LU88001 A LU 88001A LU 88001 A1 LU88001 A1 LU 88001A1
Authority
LU
Luxembourg
Prior art keywords
mixture
compounds
formula
group
epimer
Prior art date
Application number
LU88001A
Other languages
English (en)
French (fr)
Inventor
Jose Calatayud
Jose Ramon Conde
Manuel Luna
Original Assignee
Elmu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elmu Sa filed Critical Elmu Sa
Publication of LU88001A1 publication Critical patent/LU88001A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU88001A 1990-09-07 1991-09-04 Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires LU88001A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57894290A 1990-09-07 1990-09-07

Publications (1)

Publication Number Publication Date
LU88001A1 true LU88001A1 (fr) 1992-06-01

Family

ID=24314964

Family Applications (2)

Application Number Title Priority Date Filing Date
LU88001A LU88001A1 (fr) 1990-09-07 1991-09-04 Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires
LU91205C LU91205I2 (fr) 1990-09-07 2005-11-09 Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU91205C LU91205I2 (fr) 1990-09-07 2005-11-09 Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)

Country Status (18)

Country Link
US (1) US5482934A (de)
JP (1) JP3292928B2 (de)
KR (1) KR100193085B1 (de)
AT (1) AT402930B (de)
AU (1) AU649472B2 (de)
BE (1) BE1005876A5 (de)
BR (1) BR1100860A (de)
CA (1) CA2050812C (de)
CH (1) CH683343A5 (de)
DE (2) DE4129535C2 (de)
ES (1) ES2034893B1 (de)
FR (1) FR2666585B1 (de)
GB (1) GB2247680B (de)
GR (1) GR1001529B (de)
IT (1) IT1251376B (de)
LU (2) LU88001A1 (de)
NL (2) NL194917C (de)
PT (1) PT98897B (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA26230A (uk) 1990-03-02 1999-07-19 Глексо Груп Лімітед Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
DK0701565T3 (da) * 1993-04-02 1999-07-12 Byk Gulden Lomberg Chem Fab Nye prednisolonderivater
ATE198074T1 (de) * 1994-03-09 2000-12-15 Byk Gulden Lomberg Chem Fab Neue silylverbindungen und ihre verwendung
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
DE10055820C1 (de) * 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
ES2351184T3 (es) 2000-11-10 2011-02-01 Nycomed Gmbh Procedimiento para la producción de 16,17-[(ciclohexilmetilen)bis(oxil)]-11,21-dihidroxi-pregna-1,4-dien-3,20-diona o su 21-isobutirato mediante transcetalización.
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CA2495830C (en) 2002-08-30 2012-08-21 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
AU2003291634A1 (en) * 2002-10-08 2004-05-04 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
CN100404545C (zh) * 2003-03-27 2008-07-23 尼科梅德有限责任公司 具有规定粒径的结晶环缩松的制备方法
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
WO2004110460A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
JP5371189B2 (ja) * 2003-09-15 2013-12-18 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の治療のためのシクレソニドの使用
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
US20070134165A1 (en) * 2004-04-20 2007-06-14 Altana Pharma Ag Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
CN100338089C (zh) * 2004-08-12 2007-09-19 重庆医药工业研究院有限责任公司 一种哮喘病治疗药物环索奈德的新的制备方法
CA2579007A1 (en) * 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
CN100345864C (zh) * 2004-10-29 2007-10-31 天津药业研究院有限公司 一种治疗呼吸道疾病的甾体药物的制备方法及其中间体
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2006138212A1 (en) * 2005-06-14 2006-12-28 Gilead Sciences, Inc. SUBSTITUTED PHENYLPHOSPHATES AS MUTUAL PRODRUGS OF STEROIDS AND β -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION
CN1325508C (zh) * 2005-06-21 2007-07-11 浙江仙琚制药股份有限公司 一锅法制备泼尼松龙衍生物
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
CN102134269A (zh) * 2005-09-02 2011-07-27 尼科克斯公司 糖皮质激素硝酰氧基衍生物
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
JP2009512733A (ja) * 2005-11-02 2009-03-26 シコール インコーポレイティド シクレソニドの改良された製造法
WO2007092574A2 (en) * 2006-02-08 2007-08-16 Sicor, Inc. Crystalline forms of ciclesonide
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008015696A2 (en) * 2006-05-23 2008-02-07 Cadila Healthcare Limited Process for preparing ciclesonide
CA2657639A1 (en) 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
PL2074093T3 (pl) 2006-08-22 2013-03-29 Sun Pharmaceutical Ind Ltd Sposób przygotowywania inhibitorów metaloproteinazy macierzy i chiralnego środka wspomagającego
WO2008062450A2 (en) * 2006-09-18 2008-05-29 Cadila Healthcare Limited Crystalline polymorphs of ciclesonide
CA2663737A1 (en) 2006-09-19 2008-03-27 Cipla Limited Processes for the preparation of ciclesonide and its crystal form
EP2066661A2 (de) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
ATE555111T1 (de) 2006-12-19 2012-05-15 Astrazeneca Ab Chinuclidinol-derivate als muscarinrezeptor- antagonisten
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2022796A1 (de) * 2007-08-07 2009-02-11 Nycomed GmbH Amorphes Ciclesonid
US20090075959A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ciclesonide
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (de) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. 4-(2-Amino-1-hydroxyethyl)Phenol-Derivate als Agonisten des b2-adrenergen Rezeptors
JP2011513469A (ja) * 2008-03-13 2011-04-28 ファルマビオス ソシエタ ペル アチオニ プレグナン誘導体の製造法
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
BRPI0912657A2 (pt) * 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
MX2010012492A (es) 2008-05-27 2010-12-21 Astrazeneca Ab Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
WO2010104187A1 (ja) 2009-03-09 2010-09-16 三笠製薬株式会社 ステロイド化合物
EP2228368A1 (de) 2009-03-12 2010-09-15 Almirall, S.A. Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on
MX364947B (es) 2009-10-01 2019-05-15 Adare Pharmaceuticals Inc Composiciones de corticosteroides administradas oralmente.
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
WO2011093814A2 (en) 2010-01-29 2011-08-04 Mahmut Bilgic A pharmaceutical combination comprising formoterol and ciclesonide
WO2011136752A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
CN102477064B (zh) * 2010-11-23 2014-06-11 天津金耀集团有限公司 一种制备环索奈德的16,17缩酮中间体
US11007150B2 (en) 2011-08-18 2021-05-18 Covis Pharma Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation
EP2578570A1 (de) 2011-10-07 2013-04-10 Almirall, S.A. Neues Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxychinolin-2(1H)-on mittels neuen Synthesezwischenstoffen
WO2013109212A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (de) 2012-03-20 2013-09-25 Almirall, S.A. Neuartige polymorphe Kristallformen von 5-(2-{[6-(2,2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on, Heminapadisylat als Agonist des beta2-adrenergen Rezeptors
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP3250211B1 (de) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Neuartiges verfahren zur herstellung von glucocorticoidsteroiden
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN106749493A (zh) * 2017-01-09 2017-05-31 河南利华制药有限公司 一种哈西奈德中间体的制备工艺
EP3807889A1 (de) 2018-06-14 2021-04-21 AstraZeneca UK Limited Verfahren zur behandlung und vorbeugung von asthmasymptomen mit einer pharmazeutischen corticosteroid-zusammensetzung
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN120239705A (zh) * 2022-07-21 2025-07-01 萤火虫生物股份有限公司 糖皮质激素受体激动剂和其缀合物
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3079384A (en) * 1960-10-10 1963-02-26 Olin Mathieson C-ring substituted 6alpha-halo steroids and process for producing them
SE378110B (de) * 1972-05-19 1975-08-18 Bofors Ab
SE378109B (de) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
CH608244A5 (en) * 1974-02-27 1978-12-29 Pierrel Spa Process for the preparation of steroids
US4272446A (en) * 1974-02-27 1981-06-09 Pierrel S.P.A. Steroids and process for preparing the same
GB1504294A (en) * 1974-03-05 1978-03-15 Palladino G 6 beta-fluoropregnane compounds
NL7412537A (nl) * 1974-05-17 1975-11-19 Lark Spa Werkwijze voor het bereiden van 16.17-cyclische acetalen en ketalen van 9-(alpha)-halogeensteroiden.
US4036831A (en) * 1975-10-28 1977-07-19 Steroid Development Company Establishment Trimethyl siloxane steroid intermediates
DE3012888A1 (de) * 1980-03-31 1981-10-08 Schering Ag Berlin Und Bergkamen, 1000 Berlin Neue steroide und verfahren zu ihrer herstellung
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
DE3640709A1 (de) * 1986-11-28 1988-06-09 Schering Ag Verfahren zur herstellung von 6(alpha),9(alpha)-difluor-11ss,17(alpha)-dihydroxy-16(alpha)-methyl-4-pregnen-3,20-dion und dessen derivate

Also Published As

Publication number Publication date
KR920006365A (ko) 1992-04-27
PT98897A (pt) 1992-07-31
ITMI912296A1 (it) 1993-02-28
NL9101472A (nl) 1992-04-01
GR1001529B (el) 1994-03-31
GB2247680B (en) 1994-06-01
FR2666585B1 (fr) 1994-09-09
CA2050812C (en) 2003-07-29
DE122005000030I1 (de) 2005-10-06
GR910100353A (en) 1992-09-11
DE4129535A1 (de) 1992-03-12
CH683343A5 (de) 1994-02-28
HK1005881A1 (en) 1999-01-29
US5482934A (en) 1996-01-09
NL300196I1 (nl) 2005-08-01
JPH04257599A (ja) 1992-09-11
FR2666585A1 (fr) 1992-03-13
LU91205I2 (fr) 2006-05-30
CA2050812A1 (en) 1992-03-08
AT402930B (de) 1997-09-25
GB9118967D0 (en) 1991-10-23
DE122005000030I2 (de) 2007-12-06
ITMI912296A0 (it) 1991-08-28
GB2247680A (en) 1992-03-11
NL300196I2 (nl) 2005-10-03
ES2034893A1 (es) 1993-04-01
ES2034893B1 (es) 1994-01-01
BE1005876A5 (nl) 1994-02-22
KR100193085B1 (ko) 1999-06-15
PT98897B (pt) 2000-10-31
AU649472B2 (en) 1994-05-26
IT1251376B (it) 1995-05-09
DE4129535C2 (de) 2001-03-15
AU8368691A (en) 1992-03-12
ATA176991A (de) 1997-02-15
JP3292928B2 (ja) 2002-06-17
NL194917C (nl) 2003-09-01
BR1100860A (pt) 1999-08-31

Similar Documents

Publication Publication Date Title
LU88001A1 (fr) Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires
FR2584725A1 (fr) Androsta-1,4-diene-3,17-diones substituees, leur procede de fabrication et medicaments les contenant
EP0007823B1 (de) 3,20-Dioxo-4,9-dien-21-hydroxy-steroidderivate, Verfahren zu ihrer Herstellung, ihre Anwendung in Arzneimitteln und pharmazeutische Zusammensetzungen, die sie enthalten
EP0898579B1 (de) 17-alpha-unsubstituierte pregnan derivate, ihre verwendung als medikamente, ein verfahren zu ihrer herstellung und zwischenprodukte dieses verfahrens, und pharmazeutische präparate davon
EP0072268B1 (de) Steroide die, in Stellung 17 verestert sind, und in Stellung 21 eine Thioestergruppe enthalten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
CA1203234A (fr) PROCEDE DE PREPARATION DE NOUVEAUX DERIVES DICHLORES DE LA SERIE 16.alpha.-METHYL PREGNANE
EP0141684B1 (de) Hydrocortison-17-Carbonsäure-21-Thiocarbonsäure-Ester, ihre Herstellung und ihre Anwendung als Arzneimittel
EP0101383B1 (de) 14-Aminosteroidderivate, ihre therapeutische Anwendung und Verfahren zu ihrer Herstellung
EP0012641B1 (de) Substituierte-19-nor-pregn-4-en-3,20-dion-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
EP0443957B1 (de) Neue 17-spiro substituierte Steroide, Verfahren zu deren Herstellung und Zwischenprodukten davon, ihre Verwendung als Arzneimittel sowie pharmazeutische Präparate davon
PH26685A (en) Novel steroid derivatives pharmaceutical compositions containing them and method of use thereof
CA1114366A (fr) PROCEDE DE PREPARATION DE DERIVES 17.alpha.-ACETYLENIQUES DE L'ANDROST 4-ENE
EP0055170B1 (de) In Stellung 7 substituierte 3-keto-delta-4- oder -delta-1,4-Steroidderivate, ihre Herstellung, ihre Verwendung als Arzneimittel und pharmazeutische Zusammensetzungen, die sie enthalten
EP0003090B1 (de) 17 Alpha-aryle oder 17 Alpha-heteroaryle Steroide, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zubereitungen
CA1121342A (fr) Procede de preparation de nouveaux derives du pregn 4-ene
EP0059146B1 (de) Arzneimittel, abgeleitet von 3-Hydroxy-dodecahydro-benz(e)inden-7-on, Produkte, abgeleitet von 3-Hydroxy-dodecahydro-benz(e)inden-7-on und Verfahren zu ihrer Herstellung
FR2462443A1 (fr) Nouveau derive halogene de la serie du 16a-methyl pregnane, son procede de preparation et son application comme medicament
CH619969A5 (en) Process for the preparation of new halogenated derivatives of the 16alpha-methylpregnane series
EP1257568B1 (de) Echinocandin-derivate, deren herstellung und verwendung als fungizid
WO1992001706A1 (fr) Nouveaux derives de la 6-methyl 19-nor progesterone, substitue en 3 et leur procede d'obtention
FR2468617A1 (fr) Nouveaux derives acetyleniques chlores de l'androst-4-ene leur procede de preparation, et leur application a titre de medicament et les compositions pharmaceutiques les renfermant
BE594849A (de)
CH368168A (fr) Procédé de préparation de stéroïdes
BE544379A (de)

Legal Events

Date Code Title Description
CCP Supplementary protection certificate

Free format text: 91205, EXPIRES: 20160904

Spc suppl protection certif: 91205

Expiry date: 20160904